SLC5A2 and diabetes mellitus: An additional difference between SGLT2 inhibitors is the observation that there was an increased signal for lower limb amputations related to canagliflozin use in the CANVAS studies, an outcome that, although observed at a higher rate in patients with diabetes than in the general population, has not been observed in any of the empagliflozin or dapagliflozin studies to date [39–44].